Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function
- 13 May 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 20 (9) , 1429-1442
Abstract
Ceramide kinase (CERK) is the mammalian lipid kinase from which the bioactive sphingolipid, ceramide-1-phosphate (C1P), is derived. CERK has been implicated in several promalignant phenotypes with little known as to mechanistic underpinnings. In this study, the mechanism of how CERK inhibition decreases cell survival in mutant (Mut) KRAS non–small cell lung cancer (NSCLC), a major lung cancer subtype, was revealed. Specifically, NSCLC cells possessing a KRAS mutation were more responsive to inhibition, downregulation, and genetic ablation of CERK compared with those with wild-type (WT) KRAS regarding a reduction in cell survival. Inhibition of CERK induced ferroptosis in Mut KRAS NSCLC cells, which required elevating VDAC-regulated mitochondria membrane potential (MMP) and the generation of cellular reactive oxygen species (ROS). Importantly, through modulation of VDAC, CERK inhibition synergized with the first-line NSCLC treatment, cisplatin, in reducing cell survival and in vivo tumor growth. Further mechanistic studies indicated that CERK inhibition affected MMP and cell survival by limiting AKT activation and translocation to mitochondria, and thus, blocking VDAC phosphorylation and tubulin recruitment. Implications: Our findings depict how CERK inhibition may serve as a new key point in combination therapeutic strategy for NSCLC, specifically precision therapeutics targeting NSCLC possessing a KRAS mutation.Keywords
All Related Versions
Funding Information
- National Institutes of Health—National Institute of Allergy and Infectious Diseases (R01 AI139072)
- National Institute of General Medical Sciences (R01 GM137578, R01 GM137394)
- Veteran's Administration (I BX001792;)
- Senior Research Career Scientist Award (IK6BX004603;)
This publication has 80 references indexed in Scilit:
- Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2Cell Metabolism, 2013
- Ceramide Kinase Regulates the Production of Tumor Necrosis Factor α (TNFα) via Inhibition of TNFα-converting EnzymeJournal of Biological Chemistry, 2011
- SRSF1 Regulates the Alternative Splicing of Caspase 9 Via A Novel Intronic Splicing Enhancer Affecting the Chemotherapeutic Sensitivity of Non–Small Cell Lung Cancer CellsMolecular Cancer Research, 2011
- Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote TumorigenesisMolecular Cell, 2011
- C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivoCell Death & Disease, 2011
- Alternative Splicing of Caspase 9 Is Modulated by the Phosphoinositide 3-Kinase/Akt Pathway via Phosphorylation of SRp30aCancer Research, 2010
- Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasisOncogene, 2010
- Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respirationProceedings of the National Academy of Sciences, 2008
- Comprehensive Identification of PIP3-Regulated PH Domains from C. elegans to H. sapiens by Model Prediction and Live ImagingMolecular Cell, 2008
- Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signalsCell, 1995